Evidence map›Paper›PMID 41384277›Full record

Trial reportTransplant international : official journal of the European Society for Organ Transplantation2025

Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis.

Nassim Kamar, Robin K Avery, Tien Bo, Joan Gu, Deepali Kumar, Oliver Witzke

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transplant international : official journal of the European Society for Organ Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02931539 (A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02931539 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

TypeinterventionalSponsorShireRan2016 to 2020Enrolled352ConditionsCytomegalovirus (CMV)ArmsMaribavir, Ganciclovir, Valganciclovir, Foscarnet, Cidofovir
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Nurturing a Sustainable Transplantation Journey: the best of ESOT Congress 2025.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nassim KamarToulouse Rangueil University Hospital, INFINITY-Inserm U1291-CNRS U5051, University Paul Sabatier, Toulouse, France.
Robin K AverySchool of Medicine, Johns Hopkins University, Baltimore, MD, United States.
Tien BoTakeda Development Center Americas, Inc., Cambridge, MA, United States.
Joan GuTakeda Development Center Americas, Inc., Cambridge, MA, United States.
Deepali KumarAjmera Transplant Centre, University Health Network, Toronto, ON, Canada.
Oliver WitzkeDepartment of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytomegalovirus (CMV) infection following solid organ transplant (SOT) is associated with increased mortality risk. In the phase 3 SOLSTICE study (NCT02931539), more transplant recipients achieved CMV clearance after 8 weeks with maribavir than investigator-assigned therapy (IAT). In SOLSTICE, SOT recipients with refractory CMV infection were randomized 2:1 to receive maribavir or IAT for 8 weeks. This

Indexed as

Antiviral AgentsBenzimidazolesCytomegalovirus InfectionsOrgan TransplantationRibonucleosidesViremiaAdultAgedCytomegalovirusDichlororibofuranosylbenzimidazoleFemaleHumansKaplan-Meier EstimateMaleMiddle AgedTreatment OutcomeAntiviral AgentsBenzimidazolesDichlororibofuranosylbenzimidazolemaribavirRibonucleosidesanti-CMV therapyantiviralmaribavirSOT (solid organ transplant)survival

Identifiers

PMID41384277
PMCPMC12689443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.